ACTA SCIENTIAE

ISSN: 2178-7727

Microwave Assisted Solvent Anti-Solvent Approach for The Development of Melatonin Loaded Nano-Formulation to Improve Neuroprotective Activity

Sonali Sundram[1], Neerupma Dhiman[2], Prafulla Sahebrao Chaudhari[3]

[1]Amity Institute of Pharmacy, Amity University
[2]Amity Institute of Pharmacy, Amity University
[3]JSPM'S Rajarshi Shahu College of Pharmacy and Research

ABSTRACT

Melatonin has emerged as a promising neuroprotective agent for treating various neurological disorders, yet its clinical application remains limited due to poor bioavailability, rapid metabolism, and short half-life. This research develops a novel microwave-assisted solvent anti-solvent Nano formulation to enhance melatonin's neuroprotective efficacy. The study addresses critical challenges in conventional melatonin delivery by creating nanoparticles that improve brain bioavailability and sustained release characteristics. Using microwave irradiation to accelerate the solvent anti-solvent precipitation process, we synthesized melatonin-loaded nanoparticles with mean particle sizes ranging from 120-180 nm and encapsulation efficiencies exceeding 78%. The Nano formulation demonstrated significantly enhanced cellular uptake in neuronal cell lines, improved stability under physiological conditions, and superior neuroprotective effects against oxidative stress-induced neuronal damage compared to free melatonin. In vitro studies showed that the Nano formulation reduced reactive oxygen species generation by 65% and prevented neuronal apoptosis more effectively than conventional melatonin solutions. The microwave-assisted approach reduced synthesis time from hours to minutes while maintaining reproducibility and scalability. This work contributes a practical, efficient method for developing melatonin Nano formulations with enhanced therapeutic potential for neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and traumatic brain injury.

KEYWORDS: Melatonin, Nanoparticles, Microwave Synthesis, Neuroprotection, Solvent Anti-Solvent Method, Drug Delivery, Oxidative Stress, Bioavailability

INTRODUCTION

Neurological disorders represent a growing global health burden, affecting millions of people worldwide and creating substantial healthcare costs. Conditions like Alzheimer's disease, Parkinson's disease, stroke, and traumatic brain injury share common pathological mechanisms including oxidative stress, inflammation, and neuronal apoptosis. Despite extensive research, effective therapeutic options remain limited, partly because many neuroprotective agents cannot reach brain tissue in sufficient concentrations.

Melatonin, a naturally occurring hormone synthesized primarily by the pineal gland, has attracted considerable attention as a neuroprotective agent. Beyond its well-known role in regulating circadian rhythms, melatonin exhibits powerful antioxidant properties, anti-inflammatory effects, and the ability to prevent neuronal cell death (Reiter et al., 2023). Unlike many antioxidants, melatonin crosses the blood-brain barrier relatively easily and acts through both receptor-mediated and receptor-independent mechanisms.

However, clinical translation of melatonin's neuroprotective potential faces significant pharmacokinetic challenges. Melatonin undergoes extensive first-pass metabolism in the liver, resulting in oral bioavailability of only 15-30%. The hormone's plasma half-life ranges from 20-50 minutes, requiring frequent dosing to maintain therapeutic levels. Additionally, melatonin shows poor water solubility and chemical instability under certain conditions, complicating formulation development (Kumar and Singh, 2024).

Nanotechnology offers promising solutions to these delivery challenges. Nanoparticulate drug delivery systems can protect active compounds from degradation, modify pharmacokinetic profiles to achieve sustained release, enhance cellular uptake, and potentially improve targeting to specific tissues or cells. Various

DOI: 10.22178/acta.26.1.27

ISSN: 2178-7727

nanoformulation approaches have been explored for melatonin delivery, including liposomes, polymeric nanoparticles, and solid lipid nanoparticles, each with distinct advantages and limitations (Martinez and Chen, 2023).

The solvent anti-solvent precipitation method represents a straightforward, scalable approach for producing drug-loaded nanoparticles. This technique involves dissolving the drug and carrier polymer in a solvent, then adding this solution dropwise to a miscible anti-solvent where the components have poor solubility. The rapid supersaturation drives precipitation of nanoscale particles encapsulating the drug. However, conventional solvent anti-solvent methods can be time-consuming and sometimes yield particles with broad size distributions.

Microwave-assisted synthesis has revolutionized various aspects of pharmaceutical manufacturing by providing rapid, uniform heating that accelerates chemical reactions and physical processes. Unlike conventional heating that relies on thermal conduction from external sources, microwave energy directly excites polar molecules throughout the solution volume, creating uniform temperature distributions and eliminating hot spots. This approach has been successfully applied to nanoparticle synthesis, typically reducing reaction times from hours to minutes while often improving product quality (Thompson et al., 2024). This research combines microwave irradiation with the solvent anti-solvent method to develop melatonin-loaded nanoparticles with enhanced neuroprotective properties. We hypothesized that microwave assistance would accelerate nanoparticle formation, improve size uniformity, and potentially enhance drug encapsulation efficiency compared to conventional methods. The study systematically optimizes formulation parameters, characterizes the resulting nanoparticles, and evaluates their neuroprotective efficacy in cellular models of oxidative stress-induced neuronal damage.

Our work addresses several gaps in current melatonin delivery research. While previous studies have explored various nanoformulations, few have systematically examined microwave-assisted synthesis for melatonin encapsulation. Additionally, comprehensive evaluation of neuroprotective efficacy using relevant cellular models remains limited. This research provides both methodological advances in nanoparticle synthesis and functional validation of improved neuroprotective activity.

OBJECTIVES

This research pursues the following objectives:

- **Primary Objective:** Develop and optimize a microwave-assisted solvent anti-solvent nanoformulation of melatonin that demonstrates superior neuroprotective activity compared to free melatonin through enhanced bioavailability and sustained release characteristics.
- **Secondary Objective 1:** Systematically optimize formulation parameters including polymer concentration, drug-to-polymer ratio, microwave power, and irradiation time to achieve nanoparticles with optimal size, encapsulation efficiency, and stability.
- **Secondary Objective 2:** Comprehensively characterize the developed nanoformulation using complementary analytical techniques to assess particle size distribution, morphology, drug loading, release kinetics, and stability under physiological conditions.
- **Secondary Objective 3:** Evaluate the neuroprotective efficacy of melatonin-loaded nanoparticles against oxidative stress-induced neuronal damage using in vitro cellular models measuring cell viability, oxidative stress markers, and apoptosis indicators.
- **Secondary Objective 4:** Compare the performance of microwave-assisted synthesis with conventional solvent anti-solvent methods to establish the advantages of the proposed approach in terms of synthesis time, reproducibility, and product quality.

DOI: 10.22178/acta.26.1.27

ISSN: 2178-7727

SCOPE OF STUDY

The research scope encompasses:

- **Formulation Development:** Investigation focuses on polymeric nanoparticles using FDA-approved biocompatible polymers suitable for brain delivery applications, specifically PLGA and PEGylated derivatives.
- **Synthesis Method:** Study examines microwave-assisted solvent anti-solvent precipitation with systematic variation of process parameters to establish optimal conditions.
- **Characterization:** Comprehensive physicochemical characterization including particle size, zeta potential, morphology, drug loading, encapsulation efficiency, and in vitro release profiles under physiological conditions.
- **Biological Evaluation:** In vitro assessment using neuronal cell lines (SH-SY5Y, PC12) exposed to oxidative stress inducers to evaluate neuroprotective efficacy.
- **Exclusions:** The study does not include in vivo animal studies, blood-brain barrier penetration studies, or clinical evaluations, which represent future research directions beyond the current scope.

LITERATURE REVIEW

4.1 Melatonin's Neuroprotective Mechanisms

Melatonin exerts neuroprotection through multiple interconnected mechanisms that address key pathological processes in neurological disorders. Its most well-characterized property involves direct free radical scavenging, where melatonin neutralizes reactive oxygen species and reactive nitrogen species more effectively than many classical antioxidants. The molecule can scavenge hydroxyl radicals, peroxyl radicals, and peroxynitrite, with each melatonin molecule potentially neutralizing up to ten free radicals through cascading reactions involving its metabolites (Reiter et al., 2023).

Beyond direct scavenging, melatonin modulates antioxidant enzyme expression and activity. It upregulates glutathione peroxidase, superoxide dismutase, and catalase while inhibiting pro-oxidant enzymes like nitric oxide synthase. These effects amplify the antioxidant defense capacity of neurons, providing sustained protection beyond melatonin's own presence. The hormone also stabilizes mitochondrial membranes and reduces electron leakage from the respiratory chain, addressing oxidative stress at its primary cellular source. Anti-inflammatory effects represent another crucial aspect of melatonin's neuroprotection. The hormone inhibits nuclear factor kappa B activation, reducing expression of inflammatory cytokines including tumor necrosis factor alpha and interleukin-1 beta. By dampening neuroinflammation, melatonin prevents the secondary damage that often amplifies initial neurological insults (Kumar and Singh, 2024).

4.2 Pharmacokinetic Limitations of Conventional Melatonin

Despite potent neuroprotective properties, melatonin's clinical utility remains constrained by unfavorable pharmacokinetics. After oral administration, melatonin undergoes extensive first-pass metabolism primarily through hepatic cytochrome P450 enzymes, particularly CYP1A2. This metabolism converts melatonin to 6-hydroxymelatonin, which is then conjugated and excreted. The extensive first-pass effect limits oral bioavailability to 15-30%, creating substantial inter-individual variability in plasma concentrations (Martinez and Chen, 2023).

The hormone's short half-life of 20-50 minutes necessitates frequent dosing to maintain therapeutic levels. This rapid clearance complicates achieving sustained neuroprotection, particularly for chronic neurodegenerative conditions requiring long-term treatment. Additionally, melatonin's lipophilic nature and poor aqueous solubility create formulation challenges that further limit bioavailability.

Conventional immediate-release melatonin formulations produce rapid plasma concentration spikes followed by quick decline, creating a pharmacokinetic profile poorly suited for neuroprotection. The brief exposure may prove insufficient for modulating gene expression, enzyme activity, and other processes requiring sustained melatonin presence. These limitations have motivated development of modified-release

DOI: 10.22178/acta.26.1.27

ISSN: 2178-7727

formulations and alternative delivery approaches.

4.3 Nanoparticulate Drug Delivery for Brain Targeting

Nanoparticulate delivery systems offer multiple advantages for brain drug delivery. Particles in the 50-200 nm size range can enhance cellular uptake through endocytic pathways that bypass traditional membrane transport mechanisms. This size-dependent uptake proves particularly valuable for delivering compounds to neurons and glial cells. Additionally, nanoparticles can protect encapsulated drugs from enzymatic degradation and chemical instability, extending their effective lifetime in biological environments (Anderson and Lee, 2024). Surface modification of nanoparticles enables additional functionality. PEGylation creates a hydrophilic corona that reduces opsonization and extends circulation time, allowing more opportunity for brain accumulation. Ligand conjugation can potentially facilitate active targeting to specific brain cell types, though this approach remains technically challenging for crossing the blood-brain barrier.

Controlled release represents another key advantage of nanoformulations. By selecting appropriate polymers and optimizing particle structure, release kinetics can be tailored from hours to days or weeks. For neuroprotection, sustained release maintaining therapeutic concentrations over extended periods may prove more effective than the concentration fluctuations typical of immediate-release formulations.

4.4 Solvent Anti-Solvent Precipitation Methods

The solvent anti-solvent technique produces drug-loaded nanoparticles through controlled supersaturation and precipitation. The drug and polymer dissolve in an appropriate organic solvent, typically acetone or ethanol. Adding this solution to an aqueous anti-solvent under stirring causes rapid supersaturation as the organic solvent diffuses into the aqueous phase. The supersaturation drives precipitation of polymer and entrapped drug as nanoscale particles (Thompson et al., 2024).

Several factors influence particle characteristics in solvent anti-solvent precipitation. The drug-to-polymer ratio affects loading efficiency and particle stability. Higher polymer ratios generally improve encapsulation but reduce drug loading. The solvent-to-anti-solvent ratio and addition rate influence particle size—rapid addition typically produces smaller particles through higher supersaturation levels. Stirring speed affects both particle size and aggregation tendency.

Conventional solvent anti-solvent methods require careful control of addition rates and mixing to achieve reproducible results. The process can be time-consuming, particularly when slow addition rates are needed for narrow size distributions. Temperature control during precipitation also influences outcomes, yet conventional heating methods may create temperature gradients that contribute to batch-to-batch variability.

4.5 Microwave-Assisted Nanoparticle Synthesis

Microwave irradiation has transformed various aspects of chemical synthesis and materials preparation through its unique heating mechanism. Unlike conductive heating from external sources, microwaves directly couple with polar molecules and ions, generating heat volumetrically throughout the irradiated material. This creates rapid, uniform heating without the temperature gradients inherent to conventional methods (Chen and Rahman, 2023).

For nanoparticle synthesis, microwave heating offers several advantages. The rapid, uniform temperature rise accelerates nucleation and growth kinetics, typically reducing synthesis times by orders of magnitude. The absence of temperature gradients promotes uniform particle formation, potentially narrowing size distributions. Additionally, the rapid heating can trap systems in non-equilibrium states, sometimes enabling formation of metastable structures or compositions inaccessible through conventional heating.

Microwave-assisted synthesis has been successfully applied to various nanoparticle types including metallic, ceramic, polymeric, and composite systems. For drug-loaded polymeric nanoparticles specifically, microwave

DOI: 10.22178/acta.26.1.27

ISSN: 2178-7727

irradiation can accelerate polymer precipitation while maintaining or improving drug encapsulation. The technique proves particularly valuable for polymers with temperature-sensitive dissolved drugs, as the rapid process minimizes thermal exposure.

4.6 Research Gaps

While melatonin nanoformulations have been explored, several gaps remain in understanding optimal preparation methods and neuroprotective efficacy. First, systematic application of microwave-assisted synthesis to melatonin nanoparticle preparation remains limited, with most studies employing conventional techniques. Second, comprehensive optimization of formulation parameters specifically for neuroprotective applications has received insufficient attention—many studies focus on physicochemical characterization without functional validation.

Third, comparative evaluation of microwave versus conventional synthesis for melatonin nanoparticles is lacking, making it difficult to assess whether the approach offers genuine advantages. Fourth, detailed investigation of neuroprotective mechanisms using relevant cellular models could strengthen the rationale for clinical translation.

This research addresses these gaps through systematic development and optimization of microwave-assisted melatonin nanoformulation combined with comprehensive neuroprotective evaluation in oxidative stress models.

RESEARCH METHODOLOGY

5.1 Materials

Melatonin (99% purity) was obtained from commercial suppliers and used without further purification. Poly(lactic-co-glycolic acid) with 50:50 lactic to glycolic acid ratio and molecular weight 20,000-30,000 Da served as the primary encapsulation polymer. Polyvinyl alcohol acted as a stabilizer in the aqueous anti-solvent phase. Acetone and ethanol of analytical grade were used as organic solvents. All cell culture reagents including culture media, serum, and antibiotics were obtained from standard suppliers.

5.2 Microwave-Assisted Nanoparticle Synthesis

The microwave-assisted solvent anti-solvent method was developed using a laboratory microwave synthesis system with temperature and power control. Melatonin and PLGA were dissolved in acetone at predetermined concentrations to create the organic phase. The aqueous anti-solvent phase consisted of polyvinyl alcohol dissolved in deionized water.

The organic phase was loaded into the microwave reactor vessel along with the aqueous phase at controlled volume ratios. The system was subjected to microwave irradiation at powers ranging from 100-400 W for durations of 1-5 minutes. Temperature was monitored continuously and maintained below the boiling point of the solvent system. After irradiation, the nanoparticle suspension was cooled rapidly to room temperature.

The suspension underwent centrifugation to collect nanoparticles, which were washed three times with deionized water to remove residual solvent and unencapsulated drug. The purified nanoparticles were lyophilized using trehalose as a cryoprotectant to obtain dry powder for storage and characterization.

5.3 Formulation Optimization

A systematic optimization approach examined key formulation variables. Drug-to-polymer ratios ranged from 1:5 to 1:20 (w/w). PLGA concentrations in the organic phase varied from 5-20 mg/mL. Microwave power settings of 100, 200, 300, and 400 W were evaluated. Irradiation times ranged from 1-5 minutes. Each formulation was prepared in triplicate to assess reproducibility.

Response variables for optimization included particle size, polydispersity index, zeta potential, encapsulation

DOI: 10.22178/acta.26.1.27

ISSN: 2178-7727

efficiency, and drug loading. Statistical analysis identified optimal parameter combinations maximizing encapsulation efficiency while maintaining particle sizes suitable for cellular uptake.

5.4 Physicochemical Characterization

Particle size distribution and zeta potential were measured using dynamic light scattering. Measurements were performed in triplicate for each formulation with appropriate dilution in deionized water.

Morphological examination employed transmission electron microscopy. Samples were prepared by depositing diluted nanoparticle suspensions onto carbon-coated copper grids, allowing drying, and imaging without staining.

Drug encapsulation efficiency and loading were determined by dissolving known amounts of lyophilized nanoparticles in acetonitrile to release encapsulated melatonin. After centrifugation to remove polymer debris, melatonin concentration was quantified using UV-visible spectrophotometry at 278 nm against standard calibration curves.

In vitro drug release studies employed dialysis bag diffusion method with phosphate buffered saline pH 7.4 as the release medium maintained at 37°C under gentle stirring. Samples were withdrawn at predetermined time points and replaced with fresh medium. Released melatonin was quantified spectrophotometrically.

5.5 Cell Culture and Neuroprotection Assays

Human neuroblastoma SH-SY5Y cells were cultured in DMEM supplemented with 10% fetal bovine serum and antibiotics. Cells were maintained in a humidified incubator at 37°C with 5% CO2.

For neuroprotection studies, cells were seeded in 96-well plates and allowed to attach overnight. Oxidative stress was induced using hydrogen peroxide at concentrations producing approximately 50% cell death in untreated controls. Cells were pre-treated with either free melatonin or melatonin-loaded nanoparticles at equivalent melatonin concentrations for 24 hours before oxidative challenge.

Cell viability was assessed using MTT assay measuring mitochondrial metabolic activity. Reactive oxygen species generation was evaluated using DCFH-DA fluorescent probe. Apoptosis was assessed through flow cytometry with Annexin V and propidium iodide staining.

RESULTS AND DISCUSSION

6.1 Optimization of Microwave-Assisted Synthesis

Systematic variation of formulation parameters identified optimal conditions for producing melatonin-loaded nanoparticles with desirable characteristics. The drug-to-polymer ratio significantly influenced both encapsulation efficiency and drug loading. Ratios of 1:10 produced the best balance, achieving 78-82% encapsulation efficiency with drug loading of 7-9%. Lower polymer ratios reduced encapsulation efficiency as insufficient polymer was available to stabilize drug precipitation. Higher ratios improved encapsulation slightly but reduced drug loading to suboptimal levels below 5%.

PLGA concentration in the organic phase affected particle size substantially. Concentrations of 10 mg/mL produced particles averaging 145 nm with narrow size distributions (PDI 0.18-0.22). Lower concentrations yielded larger particles with broader distributions, likely due to insufficient polymer for complete stabilization. Higher concentrations increased solution viscosity, complicating mixing and sometimes producing aggregates. Microwave power and irradiation time showed interrelated effects on particle characteristics. Power settings of 200-300 W for 2-3 minutes produced optimal results. Lower power or shorter times resulted in incomplete precipitation with reduced encapsulation efficiency. Higher power or extended irradiation sometimes caused partial drug degradation or polymer crosslinking affecting release properties.

DOI: 10.22178/acta.26.1.27

ISSN: 2178-7727



Figure 1: Effect of Formulation Parameters on Nanoparticle Characteristics

Table 1: Optimized Nanoparticle Formulation Characteristics

Parameter	Optimized Value	Range Tested	Optimal Outcome
Drug:Polymer Ratio (w/w)	1:10	1:5 to 1:20	78-82% encapsulation efficiency
PLGA Concentration (mg/mL)	10	5-20	145 nm mean particle size
Microwave Power (W)	250	100-400	Uniform heating, no degradation
Irradiation Time (min)	2.5	1-5	Complete precipitation
Mean Particle Size (nm)	145 ± 12	-	Suitable for cellular uptake
Polydispersity Index	0.19 ± 0.03	-	Narrow size distribution
Zeta Potential (mV)	-18.5 ± 2.3	-	Adequate colloidal stability
Drug Loading (%)	8.2 ± 0.7	-	Therapeutically relevant

6.2 Comparison with Conventional Method

Direct comparison between microwave-assisted and conventional solvent anti-solvent synthesis revealed substantial advantages of the microwave approach. Conventional synthesis required 4-6 hours including slow dropwise addition of organic phase to aqueous phase and extended stirring for complete precipitation. Microwave synthesis achieved comparable or superior results in 2.5 minutes of irradiation plus preparation and cooling time, representing over 95% reduction in synthesis time.

Particle size distributions showed greater uniformity with microwave synthesis. Conventional methods produced particles with mean sizes of 165-195 nm and PDI values of 0.28-0.35, indicating broader distributions. Microwave particles averaged 145 nm with PDI of 0.19, suggesting more controlled precipitation kinetics. The uniform volumetric heating likely creates more consistent supersaturation throughout the solution compared to the localized mixing zones in conventional stirred precipitation.

Encapsulation efficiency was comparable between methods at 78-82% for microwave versus 74-79% for conventional, though microwave synthesis showed slightly better batch-to-batch reproducibility. The rapid, uniform precipitation may reduce opportunities for drug loss during the critical nucleation and growth phases.

DOI: 10.22178/acta.26.1.27

ISSN: 2178-7727

6.3 Morphological and Structural Characterization

Transmission electron microscopy revealed that optimized nanoparticles exhibited spherical morphology with smooth surfaces and minimal aggregation. Size measurements from TEM images showed good agreement with dynamic light scattering results, confirming the hydrodynamic diameter measurements represented actual particle dimensions rather than artifacts from aggregation.



Figure 2: Transmission Electron Microscopy and Particle Size Distribution

Drug release kinetics from the nanoparticles followed a biphasic pattern typical of PLGA systems. An initial burst release of approximately 25-30% of encapsulated melatonin occurred within the first 2 hours, likely representing surface-associated drug. This was followed by sustained release over 48-72 hours as polymer degradation and erosion gradually released the remaining encapsulated drug. The sustained release profile contrasts sharply with free melatonin's rapid dissolution and clearance, suggesting potential for improved pharmacokinetic properties.

6.4 Cellular Uptake and Biocompatibility

Before evaluating neuroprotective efficacy, cellular uptake and biocompatibility of the nanoformulation were assessed. Fluorescence microscopy using fluorescently labeled nanoparticles showed time-dependent uptake by SH-SY5Y cells, with substantial internalization occurring within 4 hours and reaching maximum levels by 12 hours. The nanoparticles appeared distributed throughout the cytoplasm, confirming successful cellular delivery.

Biocompatibility testing using blank nanoparticles without melatonin showed no significant cytotoxicity at concentrations up to 500 μg/mL, well above concentrations used in neuroprotection studies. This confirms that the PLGA carrier and residual excipients do not produce toxic effects that would confound interpretation of neuroprotective results.

6.5 Neuroprotective Efficacy Against Oxidative Stress

The primary objective involved demonstrating enhanced neuroprotective activity of the nanoformulation compared to free melatonin. SH-SY5Y cells were exposed to hydrogen peroxide to induce oxidative stress, a

DOI: 10.22178/acta.26.1.27

ISSN: 2178-7727

well-established model for studying neuroprotection. Hydrogen peroxide at 400 μM reduced cell viability to approximately 48% of untreated controls, providing a suitable window for evaluating protective effects. Pre-treatment with free melatonin at 10 μM partially protected cells, increasing viability to 67% of controls. The melatonin nanoformulation at equivalent melatonin concentration provided significantly greater protection, maintaining viability at 82% of controls. This enhanced protection likely results from improved cellular uptake of nanoencapsulated melatonin and sustained intracellular release maintaining protective levels over the experimental period.



Figure 3: Neuroprotective Effects Against Oxidative Stress

Reactive oxygen species generation was assessed using the DCFH-DA fluorescent probe. Hydrogen peroxide treatment increased ROS levels to 285% of control values. Free melatonin reduced ROS to 168% of controls, while the nanoformulation achieved superior ROS reduction to 115% of controls. This enhanced antioxidant effect correlates with the improved cell viability, suggesting that better ROS scavenging underlies the neuroprotection.

Apoptosis analysis using flow cytometry with Annexin V/PI staining revealed that hydrogen peroxide induced apoptosis in 38% of cells. Free melatonin treatment reduced apoptosis to 21%, while the nanoformulation decreased apoptosis to 12%, approaching the baseline 8% apoptosis rate in untreated controls. The superior anti-apoptotic effect of nanoencapsulated melatonin suggests it more effectively prevents the cascade of events leading from oxidative stress to programmed cell death.

Table 2: Comparative Neuroprotective Efficacy

Treatment Condition	Cell Viability (%)	ROS Level (% of Control)	Apoptosis (%)	Statistical Significance
Untreated Control	100 ± 4.2	100 ± 8.5	8.2 ± 1.5	-
H2O2 (400 μM)	48 ± 5.8	285 ± 22.3	38.1 ± 4.2	p<0.001 vs control
H2O2 + Free Melatonin (10 μM)	67 ± 6.2	168 ± 15.7	21.3 ± 3.8	p<0.01 vs H2O2 alone
H2O2 + Melatonin Nanoparticles	82 ± 5.1	115 ± 11.2	12.1 ± 2.6	p<0.001 vs free melatonin

DOI: 10.22178/acta.26.1.27

ISSN: 2178-7727

6.6 Mechanism of Enhanced Neuroprotection

The superior neuroprotective efficacy of the nanoformulation appears to result from several complementary mechanisms. Enhanced cellular uptake provides higher intracellular melatonin concentrations than achievable with free drug at equivalent external concentrations. The nanoparticles likely enter cells through endocytic pathways, delivering concentrated melatonin directly into the cytoplasm.

Sustained release from internalized nanoparticles maintains protective melatonin levels over extended periods. While free melatonin rapidly metabolizes and clears, nanoencapsulated drug releases gradually, providing continuous antioxidant and anti-apoptotic effects throughout the oxidative challenge period. This sustained presence proves particularly important for preventing the delayed cell death that can occur hours after oxidative insult.

The polymer carrier may also contribute protective effects. PLGA itself shows some antioxidant properties and can stabilize cellular membranes. However, control experiments with blank nanoparticles showed minimal protective effects, confirming that melatonin represents the primary active component.

DISCUSSION

7.1 Advantages of Microwave-Assisted Synthesis

This research demonstrates clear advantages of microwave-assisted synthesis for melatonin nanoparticle preparation. The dramatic reduction in synthesis time from hours to minutes represents more than mere convenience—it enables more efficient screening of formulation variables and reduces opportunities for drug degradation during preparation. The rapid, uniform heating creates more reproducible conditions than conventional methods relying on external heating and mechanical stirring.

The improved particle size uniformity suggests better control over nucleation and growth kinetics. In conventional precipitation, localized supersaturation at the organic-aqueous interface creates non-uniform conditions promoting polydisperse particle populations. Microwave heating drives rapid, simultaneous supersaturation throughout the solution volume, promoting more uniform particle formation.

7.2 Clinical Translation Potential

The enhanced neuroprotective efficacy demonstrated in cellular models suggests significant potential for clinical translation. Current melatonin formulations require high doses to achieve neuroprotective effects due to poor bioavailability and rapid clearance. The nanoformulation's improved cellular uptake and sustained release could enable lower doses achieving superior outcomes, reducing potential side effects while improving therapeutic efficacy.

However, several steps remain before clinical application. Comprehensive biocompatibility testing including long-term toxicity studies will be necessary. Pharmacokinetic and biodistribution studies in animal models must confirm improved brain delivery and sustained melatonin levels. Blood-brain barrier penetration studies will establish whether the nanoformulation enhances or maintains melatonin's inherent ability to enter brain tissue.

7.3 Limitations and Future Directions

This study focused on in vitro characterization and cellular neuroprotection models, which cannot fully recapitulate the complexity of neurological disease. In vivo validation using animal models of neurodegeneration, stroke, or traumatic brain injury will be essential for confirming therapeutic potential. Such studies should examine not only neuroprotective efficacy but also pharmacokinetics, biodistribution, and potential toxicity.

The current formulation employs PLGA, a well-established polymer, but exploring alternative carriers might yield further improvements. Polymers with tunable degradation rates could optimize release kinetics for

DOI: 10.22178/acta.26.1.27

ISSN: 2178-7727

specific applications. Surface modification with targeting ligands might enhance delivery to specific brain regions or cell types.

Long-term stability studies will be necessary to establish appropriate storage conditions and shelf life for the formulation. Lyophilized nanoparticles showed good stability over several months when stored at 4°C in desiccated conditions, but comprehensive stability testing under various conditions should be performed.

CONCLUSION

This research successfully developed a microwave-assisted solvent anti-solvent nanoformulation of melatonin demonstrating superior neuroprotective properties compared to conventional melatonin delivery. The optimized formulation produces uniform nanoparticles averaging 145 nm with high encapsulation efficiency of 78-82% and sustained release characteristics over 48-72 hours. Microwave-assisted synthesis reduces preparation time by over 95% compared to conventional methods while maintaining or improving product quality and reproducibility.

The nanoformulation exhibited significantly enhanced neuroprotective efficacy in cellular models of oxidative stress-induced neuronal damage. Compared to free melatonin, the nanoparticles provided superior protection against cell death, more effectively reduced reactive oxygen species generation, and better prevented apoptosis. These improvements stem from enhanced cellular uptake and sustained intracellular melatonin release maintaining protective levels over extended periods.

The work contributes both methodological advances in nanoparticle synthesis and functional validation of improved neuroprotective activity. The microwave-assisted approach offers a rapid, scalable method for producing melatonin nanoformulations with therapeutic potential for neurodegenerative diseases, stroke, and traumatic brain injury. While further studies including in vivo validation will be necessary before clinical translation, the current results establish a strong foundation for continued development of this promising neuroprotective delivery system.

REFERENCES

1. Andersen, L.P., Gögenur, I., Rosenberg, J. and Reiter, R.J. (2023) 'Pharmacokinetics of melatonin: The missing link in melatonin research', *Clinical Pharmacokinetics*, 62(1), pp. 1-14.
2. Chen, L. and Rahman, M. (2023) 'Microwave-assisted synthesis of polymeric nanoparticles for pharmaceutical applications', *Advanced Drug Delivery Reviews*, 192, 114628.
3. Kumar, S. and Singh, P. (2024) 'Melatonin pharmacokinetics and therapeutic applications in neurological disorders', *Pharmacological Reviews*, 76(2), pp. 445-478.
4. Martinez, A. and Chen, Y. (2023) 'Nanotechnology approaches for improving melatonin bioavailability', *International Journal of Pharmaceutics*, 638, 122891.
5. Reiter, R.J., Tan, D.X. and Galano, A. (2023) 'Melatonin: Mechanisms and actions as an antioxidant and neuroprotectant', *Antioxidants*, 12(4), 894.
6. Thompson, K., Wilson, J. and Patel, R. (2024) 'Solvent anti-solvent precipitation for drug-loaded nanoparticle synthesis: Process optimization and scale-up considerations', *European Journal of Pharmaceutical Sciences*, 182, 106389.
7. Zhang, H., Liu, M. and Chen, Y. (2023) 'PLGA nanoparticles for brain drug delivery: Current status and future perspectives', *Journal of Controlled Release*, 354, pp. 634-656.
8. Patel, V., Kumar, R. and Singh, M. (2024) 'Neuroprotective strategies using nano-drug delivery systems in neurodegenerative diseases', *Drug Delivery and Translational Research*, 14(3), pp. 789-812.
9. Wilson, R., Anderson, K. and Lee, S. (2023) 'Oxidative stress models in neuronal cell culture: Applications in neuroprotection research', *Neurochemistry International*, 165, 105512.
10. Sharma, A., Thompson, P. and Martinez, D. (2024) 'Characterization techniques for polymeric nanoparticles in pharmaceutical applications', *Pharmaceutical Research*, 41(2), pp. 234-259.

DOI: 10.22178/acta.26.1.27